Kala Pharmaceuticals Inc (KALA) just unveiled an update.
KALA BIO, Inc. has released a new corporate presentation focusing on ophthalmology innovation on their website, highlighting their progress in the field. Investors and those keen on the latest advancements can find insights about their upcoming report on the CHASE Phase 2b clinical trial, which is expected to reveal crucial safety and efficacy data on KPI-012 treatment for corneal defects by the end of 2024.
See more insights into KALA stock on TipRanks’ Stock Analysis page.
